Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
- Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
- 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
- Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
- Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.